Background: Somatic copy-number alterations that affect large genomic regions are a major
INTRODUCTION
Human cancer cell lines are ubiquitous experimental model for large pharmacogenomics studies seeking to define genomic predictors of drug response [1] [2] [3] [4] [5] [6] [7] [8] [9] . Highly mutable tumors accumulate approximately 8 SNVs every cell division 10 , the majority of which are passenger mutations, while whole chromosome missegregation occur once every 2-5 cell divisions 11-13 , 14 and may affect hundreds to thousands of genes. CNVs occur more frequently [10] [11] [12] [13] and can affect a larger portion of the genome; ranging from 1000s to >100 million bases per aberration, and can explain as much as 18% of variation in gene expression 15 . As such, chromosomal instability could result in an unstable cellular phenotype under different conditions and could therefore respond to different drugs.
The International Cell Line Authentication Committee (ICLAC) was formed 16, 17 to set guidelines for cell line usage in biomedical research to mitigate the issue of misidentification, contamination, and instability of genotype and phenotype. While misidentification and contamination are addressed by these standards, heterogeneity and genomic instability remain a problem. As an example, Ben-David et al. reported genetic variability across 106 cell lines with an estimated 19% discordance in non-silent mutations and 26% discordance in CNVs 18 .
They also reveal extensive subclonality and heterogeneity within isogenic strains of MCF-7 and A549 impacting cell morphology, doubling time, and drug sensitivity.
Our study explores the genetic instability of cell lines as a means to deconvolute inconsistencies between multiple large pharmacogenomic studies 6, [19] [20] [21] [22] . Upon confirming the cellular identities of cancer cell lines used in these studies, we quantified the discordance between molecular profiles and associated these discrepancies with discrepant transcriptomic and pharmacological phenotypes. Overall, we found significant differences in copy-number (CN) profiles within a small panel of cell lines that were associated to differential response to pharmacological compounds in multiple studies. Our results support the notion that the inherent karyotypic instability of cancer cell lines may have an adverse effect on the reproducibility of pharmacological screens.
METHODS

Processing of SNP arrays
We analyzed 3,631 Affymetrix Genome-Wide Human SNP 6.0 (Affy6) arrays and 668
HumanOmni2.5-Quad (Omni) arrays from 1,691 cell lines profiled by a compendium of 6 pharmacogenomic studies (Table 1) . We downloaded files using accession codes outlined in Table 1 and obtained cell line annotations from PharmacoDB (version 1.0.0) 23, 24 . We removed samples if they failed quality control metrics specific for Affy6 or Omni platforms 25 . We generated allele-specific copy-number (CN) profiles using HAPSEG/ABSOLUTE 26 and ASCAT 27 for Affy6 and Omni datasets respectively ( Figure 1 ). We segmented homologue-specific (HSCR) or total copy ratios (TCR) into 5 kb genomic bins and calculated a variance measure by reprocessing 60% of raw files from each dataset 20 times.
Comparing molecular profiles
To build a reference distribution for concordances between cell line pairs, we built a "matching" distribution consisting of concordance measurements for homonymous cell line pairs. Similarly, we calculated a "non-matching" distribution that consisted of the concordances for heteronymous (i.e. differently named) cell line pairs.
We compared genotypes between two cell lines using a Jaccard index 28 ( C ) for all SNPs found on both Affy6 and Omni array platforms. We compared CN-profiles using a variance-weighted
Pearson correlation coefficient (r) across all 5 kb genomic bins. We considered genotype and karyotype pairs as matching if the concordance score was greater than 80% or 60% respectively, or if the concordance was within 3 median absolute deviations away from the median (MADM) for the corresponding "matching" cell lines distribution ( Figure 1 ).
We accessed reprocessed drug response curves and gene expression data were accessed from the R PharmacoGx package (version 1.10.3) 23 . Expression space was represented by the landmark genes defined in the L1000 dataset 29 . We used the recomputed area above the curve (AAC) were used as measurements of drug sensitivity, where larger AACs represented drug-sensitivity 22 . We computed the distances between drug dose-response curves as the area between the curves (ABC) fitted on overlapping drug concentrations ( Figure 1 Fig. 1 ). An additional 29 of 1,013 samples in GDSC, 66 of 973 in CGP and 5 of 1,190 in CCLE samples were also removed based on the same quality control metrics.
Cell line authentication
We screened for all isogenic cell line pairs between and within datasets and identified which ones had heteronymous annotations. We described possible relationships using four different classifications: match and possible-match when cell lines originated or very likely originated from the same patient or sample (e.g., the Burkitt's lymphoma cell lines EB1 and EB2 from a 7-year old and 9-year old female respectively with no statement explicitly relating the two);
unknown when no annotations were available to make an informed classification; and mismatch when cell lines originated from different patients. We cross-referenced cell lines under the mismatch category with the registry of misidentified/contaminated cell lines established by ICLAC 16 (Fig. 2a) . We assumed that overlap of pairs with the registry are indicative of pre-established contaminations or misidentification, while the absence from the registry suggests errors during handling (Supp. Table 1 ). As validation, all CCLE isogenic heteronymous pairs were identified on the online CCLE portal as being a metastatic pair, identical lines, or derived from the same patient (Supp. Table 2 ). We also observed GDSC rectifying 34 erroneous cell lines of the 700 homonymous lines from their preceding CGP dataset. Of the 34, SW403 and NB4 were cases of misidentification, 11 failed quality control, and the rest had low genotype concordance with other datasets (Supp. Fig. 2a,b) , resulting in the reprocessed samples having significantly better concordance when compared to CCLE (p=0.001; Wilcoxon rank sum test) (Supp. Fig. 2c,d ).
These results confirm that GDSC and CCLE actively control the identity of their cell lines and update their data accordingly.
Comparison of karyotypes
We next examined whether isogenic cell lines of the mismatch category had concordant karyotypes. The pancreatic ductal adenocarcinoma cell line KCI-MOH1 was flagged as contaminated by HPAC, a cell line of the same cell type. These cell lines represented in CCLE and GDSC respectively were confirmed to be isogenic (concordance C =0.902), with concordant karyotypes (r HSCR-A : 0.857; r HSCR-B : 0.933) and transcriptomes (r expr =0.84; Supp. Fig. 3 ), with a minor shift in log2 ratios on chr2:q24.2-q37.3, chr4, and chr15:q13.2-q26.3 ( Fig. 3a) . Thus, we concluded that isogenicity of lines is a fair predictor of having similar, but not perfectly concordant molecular profiles.
Similarly, the two B-cell lymphoma cell lines OCI-LY10 and KARPAS-422 both screened in . While these two cell lines are of the same cell type, they are derived from two different patients, a 44-year old man and 73-year old female respectively. Since the OCI-LY10 cell line used in CCLE dataset had molecular profiles comparable to KARPAS-422 in both in GDSC and CCLE, we were able to conclude that the OCI-LY10 cell line used in CCLE is likely to be misidentified.
Overall, we observed that the majority of identically annotated cell lines pairs between datasets have either a discordant karyotype or genotype, but not both (Fig. 2b) . Cell lines that were discordant in both karyotype and genotype space were largely composed of CGP cell lines that were replaced in the GDSC dataset (Supp. Table 3 ). While genotype concordance is a binary classification schema for cell line authentication, the karyotype concordance score can be used as a surrogate metric to quantify the amount of CN discrepancies. While correlations greater than 0.8 presented with few to no CN discrepancies, correlations less than 0.6 often had major differences between profiles (Fig. 4 ).
Phenotypic consequence of genetic drift
To test for phenotypic consequences of discordant karyotypes in CCLE and GDSC, we When comparing drug sensitivity profiles, we found that REH and NCI-H23 were slightly more likely to be associated with a discordant drug sensitivity profile for paclitaxel (LR REH =0.52, LR NCI-H23 =0.52) and PD-0332991 (LR REH =1.16, LR NCI-H23 =1.11). REH was also more discordant for lapatinib (LR=1.25) and PHA-665752 (LR=2.02), however, the AAC values were low and may just represent variance in the drug sensitivity assay (Fig. 5 ) 6, 21, 30 . These results suggests that the discordant karyotypes may be associated with differential drug sensitivity while retaining a comparable transcriptome.
To evaluate whether these disparities in drug sensitivity profiles can be explained by CNV differences in REH and NCI-H23, we referenced the online LOBICO database 31 Comparison with Illumina Omni 2.5M Platform
To illustrate how an external dataset can be projected against those already analyzed, we compared all cell line molecular profiles against a study by the Genentech Cell Line Screening Initiative (gCSI) 7 which ran 668 cancer cell lines on the Illumina Omni 2.5M SNP-microarray platform. A cross-comparison of genotypes from gCSI to all reference datasets (CCLE, GDSC, CGP, and Pfizer) using 337,353 shared SNPs authenticated all cell line identities. Using these data, we generated usable copy-number profiles for 644/668 cell lines, the majority of which were concordant allele-specific copy-number profiles in our reference datasets (r A-allele = 0.79±0.07, r B-allele = 0.85±0.08). Breaking down this distribution for the A and B alleles, 210 and 362 cell lines with matching concordance (r > 0.8), 190 and 79 that were ambiguous (0.6 > r > 0.8), and 3 and 4 that were non-matching (r < 0.6), respectively. Overall, we observed similar trends of well-controlled isogenic cell lines with karyotypes that ranged on a continuous spectrum of discordance (Supp. Fig. 7 ).
To compare phenotypic measures, we conducted a comparison of expression and drug sensitivity profiles of 185 gCSI cell lines across 6 compounds against the CCLE dataset as both studies used similar drug sensitivity assays 6 . Overall, we showed that cell lines with CNV discordance (ambiguous) have similar gene expression profiles (match), albeit on the lower end of the correlation range (LR Match = -7.7±0.5; LR Ambiguous = -7.4±0.3; LR Non-match = -5.8±2.0); a comparison of drug sensitivity profiles also did not show discordances proportional to the severity of CNVs (Fig. 7) . While we measured a significant difference between all matching and non-matching drug sensitivity distributions (Kolmogorov-Smirnov test p<0.0001), there was a large amount of overlap between these distributions for paclitaxel and irinotecan which limited the range of discrepant values to the extremes. Overall, most cell line pairs had drug sensitivity profiles that were better explained by the matching distribution except for PSN-1, KYSE-510, and KARPAS-620 being more discordant for PD-0325901 (LR=1.60, LR=0.3, LR=0.1) and NUGC-3 being more discordant for erlotinib (LR=2.0) (Fig. 7) .
As PSN-1 had highly dissimilar karyotypes between gCSI and CCLE paired with substantially different response to the MEK-inhibitor PD-0325901, we investigated whether there were informative CNVs that could explain the difference in drug response. The most predictive LOBICO model was based on oncogenic mutations in BRAF , KRAS or NRAS , which are located at 7q34, 12p12.1, and 1p13.2 respectively. We observed an amplification of 7q34 (containing BRAF ) in gCSI relative to CCLE and equivalent copy-numbers of 12p12.1 (containing KRAS ) and 1p13.2 ( containing NRAS ). The amplification of BRAF in gCSI was concordant with increased sensitivity relative to CCLE (Supp. Fig. 8 ). While we show that CNV discordance in PSN-1 may be associated with drug sensitivity, we did not see any overlap between the predictive features with KYSE-510 and KARPAS-620, possibly due to the limited number of CNV discordances in these two cell lines. Similarly, we saw no overlap of predictive features of erlotinib sensitivity with NUGC-3, again possibly due to the limited number of CNV discordances and the highly targeted nature of erlotinib.
DISCUSSION
Our investigation of the six largest pharmacogenomic studies published to date revealed high-quality datasets with few genomic discrepancies. While we expected that~18% of cell lines would be misidentified per dataset 32 , we only detected only 6 out of 1,378 cell lines (0.4%) discordant in genetic and karyotypic identity in multiple datasets; highlighting the rigorous experimental protocols used in large-scale pharmacogenomic studies. We nominated an additional 51 cell lines with discrepant genotypes (3.7%), although the majority of these were marginally discordant. Importantly, we detected 311 heteronymous but isogenic cell lines; 186 of which likely originated from the same patient and 94 which were cases of misidentification/contamination. 33 , similar to our finding of CNV discordances associating with discrepant pharmacological responses. Not only can response to therapeutic compounds be ploidy-dependent [34] [35] [36] , but CNVs can also be rapidly acquired due to selective pressures in a few cell cycles 37, 38 . For instance, gain of isochromosome 5L in C.albicans is rapidly acquired to confer resistance to fluconazole 39 . Thus, the innate instability and heterogeneity of cancer cell lines is an essential factor to consider when considering pharmacological assays, especially as external pressures can exacerbate inherent heterogeneity.
In conclusion, our study highlights that genomic and chromosomal instability is an underestimated confounder that can result in differential pharmacological response in isogenic cell lines. While our study is limited by limited detection of smaller CNVs in the absence of normalization, we demonstrate that large-scale events have phenotypic effects and it is reasonable to expect smaller, focal events may also have an effect. We also have limited confidence to classify drug sensitivity discordance due to large variability in drug sensitivity measurements for homonymous cell lines. To enable high confidence associations between heterogeneity and drug response, we would require a well-controlled experiment between two institutes similar to Kleensang et al. 33 , or repeat drug sensitivity assays on single-cell cultures similar to Ben-David et al. 18 . Even so, our analysis shows the power of integrated pharmacogenetics data sets to cross-validate drug sensitivity results and to further refine mechanisms underpinning these associations. The commitment to open science of the investigators participating in the six contributing studies is laudable as we will continue to derive additional insight as we augment this resource with additional data. 
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Copy Ratio 3e-3 1e-2 2e-2 1e-1 2e-1 1e0 2e0 Figure 6 : A comparison of drug sensitivity profiles for the lung adenocarcinoma cell line NCI-H23 between the GDSC and CCLE datasets. The top panels illustrate divergent drug-sensitivity profiles for PD-0332991, a CDK4/6 inhibitor, and paclitaxel, a microtubule stabilizing chemotherapeutic. The middle panels illustrate top predictive models for each drug, pre-calculated by the Netherlands Cancer Institute using their LOBICO algorithm. Grey ">", "<", and "=" symbols are used to indicate instances where the GDSC line has a CNV greater than, less than, or equal to the CNV state in CCLE. The bottom panel is the GDSC and CCLE copy-number profiles quantilenormalized to make them more comparable; Tracks above and below the CNV figure corresponds to the LOBICO features for paclitaxel or PD-0332991. 
